| Literature DB >> 33410497 |
Sophie H Klasen1, Ludovic Gpm van Amelsvoort, Nicole Wh Jansen, Jos Jm Slangen, Gladys Tjin A Ton, IJmert Kant.
Abstract
OBJECTIVE: It was shown that an indicated prevention strategy (IPS), based on screening and early intervention, can considerably decrease future risk of long-term sickness absence (LTSA>28 days) over one year. Given the nature of the interventions, the potential of an effect extending beyond the original one year of follow-up might be present. This study aims to determine the efficacy of this IPS on LTSA and termination of employment contract over five years by extended follow up of IPS trials.Entities:
Mesh:
Year: 2021 PMID: 33410497 PMCID: PMC8091073 DOI: 10.5271/sjweh.3945
Source DB: PubMed Journal: Scand J Work Environ Health ISSN: 0355-3140 Impact factor: 5.024
Descriptive characteristics of study population randomized controlled trials (RCT) I and II.[SD=standard deviation.]
| Variables | RCT I | RCT II | ||||||
|---|---|---|---|---|---|---|---|---|
| Control (N=131) | Intervention (N=132) | Control (N=70) | Intervention (N=69) | |||||
| N (%) | Mean (SD) | N (%) | Mean (SD) | N (%) | Mean (SD) | N (%) | Mean (SD) | |
| Gender (male) | 90 (68.7) | 97 (73.5) | 43 (61.4) | 42 (60.9) | ||||
| Age (18–65 years) | 46.6 (8.3) | 46.3 (8.4) | 47.1 (9.5) | 48.4 (8.7) | ||||
| Highest level of education/job function [ | ||||||||
| Low | 65 (49.6) | 53 (40.2) | 6 (8.9) | 5 (7.9) | ||||
| Medium | 46 (34.9) | 63 (47.7) | 45 (67.3) | 49 (77.8) | ||||
| High | 20 (15.5) | 15 (11.5) | 16 (23.9) | 9 (14.3) | ||||
| Working hours/week | 33.9 (4.8) | 34.4 (3.9) | 34.9 (4.9) | 34.8 (4.5) | ||||
| Years working for the company | 23.5 (11.1) | 23.9 (11.0) | n.a. | n.a. | ||||
| Long-term illness | (47.5) | (54.5) | (51.5) | (59.1) | ||||
Does not add up due to missing data.
Overview efficacy of the indicated prevention strategy on sickness absence parameters for randomized controlled trial I (intention to treat analyses). [LTSA=long-term sickness absence; SD=standard deviation.]
| Follow-up period | Control group | Intervention group | Difference | P-value [ | P-value [ | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | % | Median | N | Mean (SD) | % | Median | N | Mean | % | |||
| 2-years | ||||||||||||
| Total SA duration [ | 68.4 (88.1) | 35.8 | 114 | 55.5 (76.4) | 24.0 | 125 | 12.9 | 0.164 | 0.08 | |||
| SA frequency | 5.42 (5.47) | 4.0 | 114 | 4.85 (3.83) | 4.0 | 125 | 0.57 | 0.297 | 0.089 | |||
| Percentage of LTSA [ | 26.7 | 35 | 23.5 | 31 | 3.2 | 0.306 | 0.225 | |||||
| 3-years | ||||||||||||
| Total SA duration [ | 104.3 (119.8) | 56.6 | 109 | 82.2 (105.9) | 36.02 | 119 | 22.1 | 0.099 | 0.069 | |||
| SA frequency | 7.66 (7.38) | 6.0 | 109 | 6.89 (5.30) | 6.0 | 119 | 0.77 | 0.313 | 0.078 | |||
| Percentage of LTSA [ | 36.6 | 48 | 24.2 | 32 | 12.4 | 0.011 | 0.005 | |||||
| 4-years | ||||||||||||
| Total SA duration [ | 125.2 (150.3) | 65.0 | 99 | 112.5 (150.5) | 49.5 | 114 | 12.7 | 0.485 | 0.376 | |||
| SA frequency | 9.36 (9.44) | 7.0 | 99 | 8.62 (6.36) | 7.0 | 114 | 0.74 | 0.450 | 0.091 | |||
| Percentage of LTSA [ | 35.1 | 46 | 27.3 | 36 | 7.8 | 0.042 | 0.025 | |||||
| 5-years | ||||||||||||
| Total SA duration [ | 166.3 (202.7) | 93.5 | 94 | 123.1 (167.1) | 65.0 | 101 | 43.2 | 0.06 | 0.055 | |||
| SA frequency | 11.44 (11.18) | 9.0 | 94 | 10.64 (7.59) | 9.0 | 101 | 0.80 | 0.522 | 0.135 | |||
| Percentage of LTSA [ | 35.9 | 47 | 24.2 | 32 | 11.7 | 0.019 | 0.007 | |||||
Crude analysis using Poisson regression without adjustments for covariates.
Adjusted analysis using Poisson regression for covariates: age, gender, job function and long-term illness.
Total SA duration including >28 SA days.
Percentage LTSA is calculated annually.
Figure 1ATime till first spell of LTSA (RCT I) according to the intention to treat principle (HR 0.61; 95% CI 0.41–0.90).
Figure 1BTime till exit from the company contract in months (RCT I) according to the intention to treat principle (HR 0.85; 95% CI 0.54–1.35).
Overview efficacy of the indicated prevention strategy on sickness absence parameters for randomized controlled trial I (intention to treat analyses). [LTSA=long-term sickness absence; SD=standard deviation.]
| Follow-up period | Control group | Intervention group | Difference | P-value [ | P-value [ | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | % | Median | N | Mean (SD) | % | Median | N | Mean | % | |||
| 2-years | ||||||||||||
| Total SA duration [ | 81.2 (114.2) | 29.5 | 56 | 71.1 (109.0) | 29.0 | 65 | 10.1 | 0.555 | 0.554 | |||
| SA frequency | 3.68 (2.88 | 3.0 | 56 | 3.68 (2.83) | 3.0 | 65 | 0 | 0.997 | 0.748 | |||
| Percentage of LTSA [ | 18.6 | 13 | 21.7 | 15 | -3.1 | 0.985 | 0.975 | |||||
| 3-years | ||||||||||||
| Total SA duration [ | 106.6 (135.8) | 43.5 | 50 | 110.5 (143.0) | 57.0 | 60 | -3.9 | 0.868 | 0.996 | |||
| SA frequency | 5.46 (4.04) | 4.5 | 50 | 5.47 (4.39) | 4.0 | 60 | -0.01 | 0.993 | 0.587 | |||
| Percentage of LTSA [ | 21.4 | 15 | 30.4 | 21 | -9 | 0.597 | 0.695 | |||||
| 4-years | ||||||||||||
| Total SA duration [ | 133.0 (185.2) | 36.5 | 40 | 145.7 (185.1) | 74.8 | 58 | -12.7 | 0.731 | 0.891 | |||
| SA frequency | 6.45 (5.42) | 5.0 | 40 | 6.76 (5.07) | 5.5 | 58 | -0.31 | 0.758 | 0.930 | |||
| Percentage of LTSA [ | 17.1 | 12 | 30.4 | 21 | -13.3 | 0.547 | 0.746 | |||||
| 5-years | ||||||||||||
| Total SA duration [ | 170.5 (249.0) | 54.1 | 33 | 197.6 (251.3) | 98.0 | 47 | -27.05 | 0.596 | 0.776 | |||
| SA frequency | 7.15 (5.97) | 6.0 | 33 | 8.08 (5.83) | 7.0 | 47 | -0.93 | 0.459 | 0.777 | |||
| Percentage of LTSA [ | 17.1 | 12 | 29.0 | 20 | -11.9 | 0.619 | 0.786 | |||||
Crude analysis using Poisson regression without adjustments for covariates.
Adjusted analysis using Poisson regression for covariates; age, gender, education level and long-term illness.
Total SA duration including >28 SA days.
Percentage LTSA is calculated annually.
Figure 2ATime till first onset of LTSA (RCT II intention to treat principle) (HR 1.31, 95% CI 0.70–2.47).
Figure 2BTime till termination of the employment contract with the company in months (RCT II intention to treat) (HR 0.62, 95% CI 0.39–0.99).